Clinical Significance of Psychiatric Comorbidities Among Outpatients With Gambling Disorder in Japan: A 12‐Month Follow‐Up Study
Neuropsychopharmacology Reports · 2025
DOI: 10.1002/npr2.70016 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, 2025. Verfasst von Risa Yamada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, To…. Hauptthemen laut MEDLINE: Gambling, Mental Disorders, Anxiety Disorders, Major Depressive Disorder. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jikei University Research Fund for Graduate Students, Japan Society for the Promotion of Science, Health and Labor Sciences Research Grant.
Abstract (Originalsprache)
Background
Gambling disorder (GD) is often comorbid with other psychiatric disorders. Previous studies have reported that psychiatric comorbidity increases both treatment dropout and relapse among patients with GD. However, little is known about the effects of comorbidity among outpatients with GD either during or after treatment. This study examined this issue in a clinical setting.
Method
60 outpatients with GD (men/women, 58/2; average age, 37.9 years) participated in assessments of the course of multidimensional treatment outcomes (i.e., gambling‐related variables, social impairment, and depressive symptoms) at three time points (baseline, 3 months, and 12 months). We examined treatment outcomes in GD patients with and without comorbidity.
Results
A total of 58.3% of the patients had comorbidities (major depressive disorder, 26.7%; behavioral addiction, 21.7%; anxiety disorder, 15.0%, etc.), while the dropout rates across the study period were 13.3% at 3 months and 35.0% at 12 months. Statistical analyses indicated that the South Oaks Gambling Screen score and the Sheehan Disability Scale score were significantly reduced at follow‐up compared to baseline in both comorbid and non‐comorbid outpatients. There was a significant difference for being still in treatment, where the proportion of individuals with comorbid disorders was significantly higher than those without comorbidities at the 12‐month compared to the 3‐month follow‐up. The proportion of all outpatients who remained abstinent from gambling at 12 months was significantly lower compared to baseline and at 3 months.
Conclusions
Being still in treatment for comorbid psychiatric problems may affect the course and outcome of GD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan.
- Department of Psychiatry, The Jikei University School of Medicine, Tokyo, Japan.
- Hirakawa Hospital, Tokyo, Japan.
ORCID-Profile: Risa Yamada, Andrew Stickley
Förderung
- Jikei University Research Fund for Graduate Students
- Japan Society for the Promotion of Science
- Health and Labor Sciences Research Grant
- Smoking Research Foundation
Zitieren
APA
Yamada, R., Stickley, A., Shigeta, M., & Miyata, H. (2025). Clinical Significance of Psychiatric Comorbidities Among Outpatients With Gambling Disorder in Japan: A 12‐Month Follow‐Up Study. Neuropsychopharmacology Reports. https://doi.org/10.1002/npr2.70016
Vancouver
Yamada R, Stickley A, Shigeta M, Miyata H. Clinical Significance of Psychiatric Comorbidities Among Outpatients With Gambling Disorder in Japan: A 12‐Month Follow‐Up Study. Neuropsychopharmacology Reports. 2025. doi:10.1002/npr2.70016
BibTeX
@article{Yamada2025,
author = {Yamada, Risa and Stickley, Andrew and Shigeta, Masahiro and Miyata, Hisatsugu},
title = {Clinical Significance of Psychiatric Comorbidities Among Outpatients With Gambling Disorder in Japan: A 12‐Month Follow‐Up Study},
journal = {Neuropsychopharmacology Reports},
year = {2025},
doi = {10.1002/npr2.70016}
}
EUVIMED